- Patients with migraine who received ubrogepant reported significantly greater relief from acute pain at 2 hours than patients who received a placebo.
- Patients who received a higher 50-mg dose also reported greater relief at 2 hours from the most bothersome migraine symptoms, such as photophobia, phonophobia, and nausea.
Why this matters
- Although there are a number of medications available to treat acute migraine pain, some patients cannot take them because of contraindications.
- Phase 3 (ACHIEVE II), double-blind, placebo-controlled, parallel-group study.
- Patients with migraine were randomly assigned to receive ubrogepant 50 mg (n=562), 25 mg (n=561), or placebo (n=563).
- Funding: Allergan plc.
- Percentage of patients relieved from pain at 2 hours with ubrogepant vs placebo (14.3% of patients):
- 50 mg: 21.8% (OR, 1.62; absolute difference [AD], 7.5%; Padjusted=.01).
- 25 mg: 20.7% (OR, 1.56; AD, 6.4%; Padjusted=.03).
- Absence of most bothersome (included photophobia, phonophobia, and nausea) migraine-associated symptom at 2 hours with ubrogepant vs placebo (27.4% patients):
- 50 mg: 38.9% (OR, 1.65; AD, 11.5%; Padjusted=.01).
- 25 mg: 34.1% (OR, 1.37; AD, 6.7%; Padjusted=.07).
- Common adverse events noted with ubrogepant doses 50 mg, 25 mg, and placebo were:
- nausea (2.0%, 2.5%, and 2.0%, respectively) and
- dizziness (1.4%, 2.1%, and 1.6%, respectively).
- Single-attack trial.
Coauthored with Chitra Ravi, MPharm